Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi-Aventis plans Multaq NDA resubmission in 2008

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA issued a "not approvable" letter for Sanofi-Aventis' Multaq (dronedarone) for treatment of atrial fibrillation/atrial flutter on Aug. 31. The company says it will resubmit the NDA in 2008 to include data from the ongoing ATHENA trial. Sanofi recently expanded the ATHENA sample size from 3,700 to 4,300 patients to attain the planned event rates. The dronedarone NDA was submitted in June 2005 based on the EURIDIS and ADONIS trials (1Pharmaceutical Approvals Monthly December 2005, p. 10)...

Related Content

Sanofi-Aventis Eyes April User Fee Goal For Anti-Arrythmic Dronedarone





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts